Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Goldschmidt, Hartmut [VerfasserIn]   i
 Cremer, Friedrich Walter [VerfasserIn]   i
 Möhler, Thomas [VerfasserIn]   i
 Krämer, Alwin [VerfasserIn]   i
 Görner, Martin [VerfasserIn]   i
 Egerer, Gerlinde [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
Titel:Therapy of multiple myeloma
Verf.angabe:H. Goldschmidt, F.W. Cremer, Th. Möhler, A. Krämer, M. Görner, G. Egerer, A.D. Ho
E-Jahr:2002
Jahr:01 September 2002
Umfang:4 S.
Fussnoten:Gesehen am 11.02.2022
Titel Quelle:Enthalten in: The Chinese-german journal of clinical oncology
Ort Quelle:Berlin : Springer, 2002
Jahr Quelle:2002
Band/Heft Quelle:1(2002), 3, Seite 141-144
ISSN Quelle:1613-9089
Abstract:Multiple Myeloma (MM) is characterised by the accumulation of malignant plasma cells in the bone marrow producing a monoclonal immunoglobulin. The standard conventional therapy is the combination of melphalan and prednisone resulting in a response rate of 40%-60% and in a median survival time of approximately 3 years. In order to improve the therapeutic efficacy various combination regimens have been tested. Most randomized trials have frailed to show a significant improvement in survival time when combination chemotherapy is used instead of melphalan with or without prednisone. The benefit of maintenance therapy with interferon-alpha has been demonstrated. The toxicity of interferon-alpha, which may reduce the quality of life, should be considered. Recently, myeloma-treatment has been modified. High-dose chemotherapy accompanied by hematopoietic stem-cell support via autologous transplant is recommended up to the age of 65-70 years. First results from a French study comparing single versus double autologous transplantation have shown a benefit in terms of event-free survival for the sequential approach. Vaccinations as an adoptive immuntherapy to treat minimal residual disease are under way. The mortality rate of allogeneic transplantation of hematopoietic stem cells has been reduced in the last 5 years. The use of reduced conditioning regimens or the partial depletion of T cells in peripheral blood stem cell transplants in an effort to decrease transplant related mortality are promising approaches. Thalidomide and its derivates are a new class of agents with independent anti-tumour activity in MM. Encouraging results with this antiangiogenic therapy in phase II trials have been reported. Supportive therapies, such as the treatment of anaemia with erythropoietin, the management of renal failure and the use of bisphosphonates, improve the life quality of MM patients.
DOI:doi:10.1007/BF02851708
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1007/BF02851708
 DOI: https://doi.org/10.1007/BF02851708
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1789449839
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68877163   QR-Code
zum Seitenanfang